Biosimilars: Save Billions or Stick with Humira?

KFF Health News, formerly Kaiser Health News, the national newsroom focused on health issues, reports in the Los Angeles Times that the savings that could be seen from biosimilars aren’t here yet. “For real competition to take hold, the big pharmacy benefit managers, or PBMs, the companies that negotiate prices and set the prescription drug menu for 80% of insured patients in the United States, would have to position the new drugs favorably in health plans,” the article states. Our own Rich Lieblich, SVP for clinical services and industry relations, shared how Prescryptive switched 100% of our patients with no interruption of therapy and no complaints. Read more in KFF Health News.